PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: AnaSpec, Inc.

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Homo-Amino Acids Provide Novel Options for Drug Discovery - AnaSpec, Inc. is a leading provider of integrated proteomics solutions for worldwide life science research.
Homo-Amino Acids Provide Novel Options for Drug Discovery

 

NewswireToday - /newswire/ - San Jose, CA, United States, 2006/10/16 - AnaSpec, Inc. is a leading provider of integrated proteomics solutions for worldwide life science research..

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

The prefixing of “homo” to the name of an amino acid indicates the addition of a methylene (CH2) group on the a-carbon of an amino acid1,2. These are used for creating peptide analogs that have may have altered biological activity. An example is shown in Shimizu’s paper3 where certain amino acids in the parathyroid hormone peptide PTH (1-14) have been substituted with Aib (aminoisobutyric acid) and homoarginine. This shorter N-terminal fragment is found to be as potent as PTH (1-34) for stimulating cAMP formation in PTH-1 receptor-expressing cells.

AnaSpec, a leading provider of integrated proteomics solutions, provides a source of homo-amino acids suited for either drug discovery or investigation of peptide biological activity.

Homo-Amino Acids:

· Fmoc-homoarginine(Pbf)-OH
· Fmoc-S-trityl-L-homocysteine
· Boc-S-trityl-L-homocysteine
· Fmoc-L-homophenylalanine
· Fmoc-D-homophenylalanine
· Fmoc-homoproline-OH or Fmoc-Pip-OH

With a vision for innovation through synergy, AnaSpec offers expertise in three primary technologies: peptides, detection reagents, and combinatorial chemistry. AnaSpec carries a broad product line of biochemicals and reagents for basic research, high-throughput screening and drug discovery. In conjunction, AnaSpec provides premier custom services including peptide synthesis, antibody production, and assay development. AnaSpec holds a California Drug Manufacturing License (License #41747) and a FDA Registration for GMP Drug Manufacturing (Registration #2951078).

References:

1. Internet. Nomenclature and Symbolism for Amino Acids and Peptides.
2. IUPAC Commission on the Nomenclature of Organic Chemistry (CNOC). Nomenclature of Organic Chemistry, Section F: Natural Products and Related Compounds, Recommendations 1976, Eur. J. Biochem. 86, 1 (1978).
3. Shimizu, N. et al. J. Bone & Mineral Res. 19, 2078 (2004).

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: AnaSpec, Inc.

 
 

Availability: All Metropolitan Area

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Homo-Amino Acids Provide Novel Options for Drug Discovery

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Debra Thai 
408-452-5055 marketing[.]anaspec.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any AnaSpec, Inc. securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From AnaSpec, Inc. / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

PleurX™ Catheter System Receives FDA 510(k) Clearance for Specific Non-Malignant Recurrent Pleural Effusions
Greenphire and Exostar Partner to Deliver Seamless, Secure Access to Clinical Research Site Payment Solution
First Pulmonary Embolism Patients in Hong Kong Treated with the EKOS® System
Ipsen to Acquire Oncology Assets from Merrimack Pharmaceuticals
FDA Grants Genentech’s Cancer Immunotherapy Tecentriq® (Atezolizumab) Priority Review in Additional Type of Advanced Bladder Cancer
FDA Approves Genentech’s Lucentis® (Ranibizumab Injection) for Myopic Choroidal Neovascularization
Sugar Element of Keratan Sulfate Halts the Progress of Emphysema Finds RIKEN
Exelixis and Ipsen Amend Exclusive Licensing Agreement for the Commercialization and Development of Cabozantinib to Include Canada
FDA Extends Review of Application for OCREVUS™ (Ocrelizumab)
MDxHealth Announces AceCGT Life Science Limited as the Exclusive Distributor for SelectMDx in Hong Kong and Macao China
Pulse Certified As A Level Four Multichannel Content Agency by Veeva Systems
BD Launches Advanced Prefillable Syringe for Higher Volume Injection of Biologics
Sartorius Announces Expansion of Sartorius Stedim Cellca
Frost & Sullivan Commends Nemaura for Developing Superior Transdermal Drug Delivery Technology Platforms, the Memspatch and Micropatch
Greenphire Sponsors Second Annual Clinical Trial Agreements, Investigator Payments and Fair Market Value Meeting

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  La Bella Bakery Artisan Bakery Arizona

Visit  Al Rowaad Advocates & Legal Consultants





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)